sympopost

1. Which of the following is true relative to the approval process for biosimilar medications in the United States?

2. Which of the following is false about switching patients from a reference product to a biosimilar?

3. Which of the following is incorrect regarding anti-CD20 monoclonal antibody use in multiple sclerosis:

4. Which of the following is correct with respect to anti-CD20 monoclonal antibody usage during pregnancy and breastfeeding?

5. MS pathogenesis involves:

6. CD40 is:

Name

First NameLast Name

Degree(s)

Email

example@example.com

Institution

Which of the following best describes your title?

***If PharmD, please provide NABP ID#:

***If PharmD, please provide DOB:

Date

How many years have you been in practice?

How many patients with atrial fibrillation do you typically see each month?

Please rate the extent to which this activity met the following objectives:

Rows	Poor	Fair	Good	Very Good	Excellent
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of biosimilar therapeutics in treatment planning
Develop treatment plans to delay disability and progression in patients with MS
Review and analyze clinical trial data for biosimilar therapeutics to manage patients with MS
Review strategies to assess individualized patient characteristics and disease prognosis to determine the role of CD20 in treatment planning
Develop treatment plans to delay disability and progression in patients with RMS
Review and analyze clinical trial data for CD20 therapeutics to manage patients with RMS
Review the current clinical trial data of CD40/CD40L inhibitors to manage patients with relapsing MS
Discuss how a CD40/CD40L would impact current treatment strategies for patients with relapsing MS

Do you feel this activity was fair balanced and free of commercial bias?

If no, please explain:

This educational activity will result in a change in my role as a healthcare team member.

This educational activity will result in a change in my practice behavior.

Based on your participation in this activity, choose the statement(s) that applies to how your role as a healthcare team member will change:

Course Title

Date

Credits

Attestation to time spent on activity:

AcademicCME designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credits™, 2.0 CNE Contact Hours (Provider #P0491) or 2.0 CPE Contact Hours (0.20 CEUs) UAN #JA4008190-0000-26-002-L01-P.

Please select your credit type from the below:

AcademicCME thanks you for your participation in this activity.
All information provided improves the scope and purpose of our programs.